Phase 3 N=564 2-arm Trial of Paclitaxel Plus Bevacizumab vs. Capecitabine Plus Bevacizumab
Metastatic Breast Cancer
Primary: Overall Survival (PP Population) — 30.2; 26.1 months — p=0.1983
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=380 Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line in Postmenopausal Women
Breast Cancer
Primary: Progression-free Survival (PFS) — 14.4; 19.3 Months
Phase 2 N=56 A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
Locally Recurrent · Metastatic Breast Cancer ( HER2 Negative)
Primary: Objective Response Rate (ORR) — 28.6 Percentage of participants
Phase 3 N=652 Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer
Breast Cancer
Primary: Progression Free Survival (PFS) at the Time of Primary Results — 8.97; 11.30; 9.13; 13.63 Months — p=0.0010
Phase 2 N=27 Trastuzumab and Erlotinib as First-Line Therapy in Treating Women With Metastatic Breast Cancer Associated With HER2/Neu Overexpression
Breast Cancer
Primary: The Objective Response Rate as Defined as Stable Disease or the Rate of Complete and Partial Responses Determined on Two Consecutive Occasions Greater Than or Equal to 4…
Phase 2 N=53 Monotherapy With Eribulin In Her2 Negative Metastatic Breast Cancer as a First Line Treatment
Breast Neoplasm · Metastasis
Primary: Time to Progression — 4.1 months
Phase 2 N=78 Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Progression-Free Survival (PFS) of MTD/Phase II Patients — 4.0 months
Phase 2 N=60 Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC
Neoplasms, Breast
Primary: Overall Tumor Response (OR) — 53 percentage of participants
Phase 2 N=44 A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer
Breast Cancer
Primary: Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) According to the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0…
Phase 2 N=109 A Study of Herceptin (Trastuzumab) in Combination With 2nd-Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.
Breast Cancer
Primary: Median Time to Disease Progression — 171; 171 Days
Phase 2 N=141 Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer
Breast Cancer
Primary: Pathologic Complete Response in Breast and Axillary Lymph Nodes. — 16; 14; 21; 5 Participants
Phase 2 N=102 Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients
Breast Cancer
Primary: Complete Pathological Response (pCR) Rate in Breast and Axilla According to the Miller&Payne Criteria (G5-A and G5-D). — 23.5; 47.9 percentage of participants with pCR
Phase 2 N=90 A Study of Avastin (Bevacizumab) in Combination With Taxane-based Chemotherapy as First Line Treatment in Patients With HER-2 Negative Breast Cancer
Breast Cancer
Primary: Progression-free Survival — 11.51 Months
Phase 2 N=52 Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer
Breast Cancer
Primary: Objective Response Rate — 71.2 Percentage of participants
Phase 2 N=144 A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Breast Neoplasms
Primary: Stage 1: Percentage of Participants With Objective Response — 10.0; 10.0; 26.9; 16.7 percentage of participants
Phase 4 N=109 A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer
Breast Cancer
Primary: Overall Survival — 505 Days
Phase 2 N=25 Trastuzumab and Oxaliplatin in Patients With Metastatic Breast Cancer
Breast Cancer
Primary: Objective Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment — 20 percentage of participants
Phase 2 N=57 Lapatinib Combined With Paclitaxel For Patients With First-Line ErbB2-Amplified Metastatic Breast Cancer
Neoplasms, Breast
Primary: Number of Participants With a Best Overall Response (OR) of Confirmed Complete Response (CR) or Partial Response (PR), as Assessed by the Independent Review Committee…
Phase 2 N=30 Neoadjuvant Chemotherapy + Herceptin in HER2 Positive Stage II-III Breast Cancer Patients
Breast Neoplasm
Primary: Percentage of Subjects Able to Complete > 85% of the Planned Dose on Schedule — 60 percentage of participants
Phase 2 N=32 Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer.
Breast Cancer
Primary: Percent of Patients Who Achieve a pCR — 19; 2; 0; 0 Participants
Phase 3 N=808 A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Progression-Free Survival (PFS) Determined by an Independent Review Facility — 18.5; 12.4 Months — p=<0.0001
Phase 3 N=1,486 A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)
Breast Cancer
Primary: Invasive Disease-free Survival (IDFS) Rate at 3 Years — 77.12; 88.44 percentage of participants — p=<0.0001
Phase 2 N=189 Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients
Breast Cancer
Primary: Pathological Response for Basal Group 2 — 16; 14; 5; 11 Participants
Phase 2 N=406 Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Breast Cancer · Carcinoma of the Breast
Primary: 3-year Disease Free Survival (DFS) Rate — 0.987 proportion of participant
Phase 2 N=43 BYL719 and Nab-Paclitaxel in Locally Recurrent or Metastatic HER-2 Negative Breast Cancer
Breast Cancer
Primary: Phase I: Recommended Phase II Dose (RP2D) of BYL-719 (Alpelisib) + Nab-paclitaxel to be Used in Combination to Treat Advanced HER2-negative Breast Cancer — 350 mg
Phase 2 N=21 Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer
Breast Cancer · Metastatic Breast Cancer
Primary: Percentage of Participants With Pathologic Complete Response (pCR) — 38.9 percentage of participants
Phase 2 N=60 Carboplatin, Abraxane, Avastin as Neoadjuvant Therapy for Her2-Negative Breast Cancer
Breast Cancer
Primary: Pathological Complete Response Rates at Surgery — 16; 2 participants
Phase 2 N=225 A Study of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Advanced and/or Metastatic Breast Cancer
Breast Cancer
Primary: Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumors…
Phase 3 N=1,436 A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer
Breast Neoplasms
Primary: Overview of the Number of Participants With at Least One Treatment-Emergent Adverse Event, Severity Determined According to National Cancer Institute Common Terminology…
Phase 2 N=95 Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer
Breast Cancer
Primary: Number of Patients Who Completed All Planned Therapy — 45 participants